Risk Factors for Development of Superior Limbic Keratoconjunctivitis in Thyroid Eye Disease in Japanese

Overview

Journal Graefes Arch Clin Exp Ophthalmol

Specialty Ophthalmology

Date 2022 Sep 9

PMID 36083323

Authors

Yasuhiro Takahashi

Aric Vaidya

Hirohiko Kakizaki

Affiliations

Soon will be listed here.

Abstract

Purpose: To analyse risk factors for the development of superior limbic keratoconjunctivitis (SLK) in thyroid eye disease (TED).

Methods: This prospective, observational study included 638 eyes/sides from 319 patients with TED. The eyes were classified into two groups, based on the presence and absence of SLK. Multivariate logistic regression analysis was performed to evaluate potential risk factors, including sex, patient age, past treatment history (steroid, orbital radiotherapy and radioiodine therapy), smoking, clinical activity score, margin reflex distance (MRD)-1 and -2, Graefe sign/lid lag, Hertel exophthalmometric results, Schirmer's test results, tear break-up time (TBUT) and tear meniscus height (TMH).

Results: SLK was found in 198 eyes (31.0%) from 121 patients. Young age (OR, 0.977; P = 0.006), smoker (OR, 1.785; P = 0.009), presence of Graefe sign (OR, 2.912; P < 0.001), absence of lid lag (OR, 0.485; P = 0.031), high Hertel exophthalmometric values (OR, 1.125; P = 0.002), shorter Schirmer's test results (OR, 0.962; P < 0.001), shorter TBUT (OR, 0.815; P = 0.002) and high upper TMH (OR, 1.003; P = 0.013) were associated with the development of SLK. A high MRD-1 measurement value also tended to be associated with a risk of SLK, with an OR of 1.187 (P = 0.056).

Conclusion: The present study proposed several risk factors in relation to the development of SLK in TED.

References

Lahoti S, Weiss M, A Johnson D, Kheirkhah A . Superior limbic keratoconjunctivitis: a comprehensive review. Surv Ophthalmol. 2021; 67(2):331-341. DOI: 10.1016/j.survophthal.2021.05.009. View

Rodriguez-Garcia A, Macias-Rodriguez Y, Gonzalez-Gonzalez J . Efficacy and safety of 0.1% lodoxamide for the long-term treatment of superior limbic keratoconjunctivitis. Int Ophthalmol. 2017; 38(3):1243-1249. DOI: 10.1007/s10792-017-0588-1. View

Nelson J . Superior limbic keratoconjunctivitis (SLK). Eye (Lond). 1989; 3 ( Pt 2):180-9. DOI: 10.1038/eye.1989.26. View

Kadrmas E, Bartley G . Superior limbic keratoconjunctivitis. A prognostic sign for severe Graves ophthalmopathy. Ophthalmology. 1995; 102(10):1472-5. DOI: 10.1016/s0161-6420(95)30843-3. View

Wei Y, Chen W, Hu F, Liao S . In vivo confocal microscopy of bulbar conjunctiva in patients with Graves' ophthalmopathy. J Formos Med Assoc. 2013; 114(10):965-72. DOI: 10.1016/j.jfma.2013.10.003. View

Chelala E, El Rami H, Dirani A, Fakhoury H, Fadlallah A . Extensive superior limbic keratoconjunctivitis in Graves' disease: case report and mini-review of the literature. Clin Ophthalmol. 2015; 9:467-8. PMC: 4362972. DOI: 10.2147/OPTH.S79561. View

Wright P . Superior limbic keratoconjunctivitis. Trans Ophthalmol Soc U K (1962). 1972; 92:555-60. View

Wilson 2nd F, Ostler H . Superior limbic keratoconjunctivitis. Int Ophthalmol Clin. 1986; 26(4):99-112. DOI: 10.1097/00004397-198602640-00010. View

Murakami Y, Kanamoto T, Tuboi T, Maeda T, Inoue Y . Evaluation of extraocular muscle enlargement in dysthyroid ophthalmopathy. Jpn J Ophthalmol. 2002; 45(6):622-7. DOI: 10.1016/s0021-5155(01)00407-5. View

10.

Lo C, Yang M, Rootman D . Natural history of inflammatory and non-inflammatory dry eye in thyroid eye disease. Orbit. 2020; 40(5):389-393. DOI: 10.1080/01676830.2020.1814352. View

11.

Takahashi Y, Ichinose A, Kakizaki H . Topical rebamipide treatment for superior limbic keratoconjunctivitis in patients with thyroid eye disease. Am J Ophthalmol. 2014; 157(4):807-812.e2. DOI: 10.1016/j.ajo.2013.12.027. View

12.

Takahashi Y, Lee P, Vaidya A, Kono S, Kakizaki H . Tear film break-up patterns in thyroid eye disease. Sci Rep. 2021; 11(1):5288. PMC: 7935998. DOI: 10.1038/s41598-021-84661-4. View

13.

Takahashi Y, Vaidya A, Kakizaki H . Changes in Eyelid Pressure and Dry Eye Status after Orbital Decompression in Thyroid Eye Disease. J Clin Med. 2021; 10(16). PMC: 8396827. DOI: 10.3390/jcm10163687. View

14.

Inoue S, Kawashima M, Arita R, Kozaki A, Tsubota K . Investigation of Meibomian Gland Function and Dry Eye Disease in Patients with Graves' Ophthalmopathy. J Clin Med. 2020; 9(9). PMC: 7565905. DOI: 10.3390/jcm9092814. View

15.

Selter J, Gire A, Sikder S . The relationship between Graves' ophthalmopathy and dry eye syndrome. Clin Ophthalmol. 2015; 9:57-62. PMC: 4287254. DOI: 10.2147/OPTH.S76583. View

16.

Muller-Forell W, Kahaly G . Neuroimaging of Graves' orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012; 26(3):259-71. DOI: 10.1016/j.beem.2011.11.009. View

17.

Ishikawa E, Takahashi Y, Valencia M, Ana-Magadia M, Kakizaki H . Asymmetric lacrimal gland enlargement: an indicator for detection of pathological entities other than thyroid eye disease. Graefes Arch Clin Exp Ophthalmol. 2018; 257(2):405-411. DOI: 10.1007/s00417-018-4197-0. View

18.

Perros P, Zarkovic M, Panagiotou G, Azzolini C, Ayvaz G, Baldeschi L . Asymmetry indicates more severe and active disease in Graves' orbitopathy: results from a prospective cross-sectional multicentre study. J Endocrinol Invest. 2020; 43(12):1717-1722. PMC: 7652741. DOI: 10.1007/s40618-020-01258-w. View

19.

Nunery W, MARTIN R, Heinz G, Gavin T . The association of cigarette smoking with clinical subtypes of ophthalmic Graves' disease. Ophthalmic Plast Reconstr Surg. 1993; 9(2):77-82. DOI: 10.1097/00002341-199306000-00001. View

20.

Mourits M, Koornneef L, Wiersinga W, Prummel M, Berghout A, van der Gaag R . Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol. 1989; 73(8):639-44. PMC: 1041835. DOI: 10.1136/bjo.73.8.639. View